Nowadays, new medicines targeting specific molecules, such as farnesoid X receptor, PPARs, and GLP-1 receptor, have been discovered and shown beneficial effects on patients with NAFLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.